Mohammad Hossein Mohammadi

Mr. Mohammad Hossein Mohammadi


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2016 in Micromachines
Verified
Journal Article
Open access
PDF file
Ahmad Rezaei KolahchiAhmad Rezaei Kolahchi
Ahmad Rezaei Kolahchi
NMNima Khadem Mohtaram
Nima Khadem Mohtaram
HMHassan Pezeshgi Modarres
Hassan Pezeshgi Modarres
MMMohammad Hossein Mohammadi
Mohammad Hossein Mohammadi
ANArmin Geraili Nejadfomeshi
Armin Geraili Nejadfomeshi
ASAmir Sanati-Nezhad
Amir Sanati-Nezhad
Development of predictive multi-organ models before implementing costly clinical trials is central for screening the toxicity, efficacy, and side effects of new therapeutic agents. Despite significant efforts that have been recently made to develop biomimetic in vitro tissue models, the clinical application of such platforms is still far from reality. Recent advances in physiologically-based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling, micro- and nanotechnology, and in silico modeling have enabled single- and multi-organ platforms for investigation of new chemical agents and tissue-tissue interactions. This review provides an overview of the principles of designing microfluidic-based organ-on-chip models for drug testing and highlights current state-of-the-art in developing predictive multi-organ models for studying the cross-talk of interconnected organs. We further discuss the challenges associated with establishing a predictive body-on-chip (BOC) model such as the scaling, cell types, the common medium, and principles of the study design for characterizing the interaction of drugs with multiple targets.